New IPO News | Inventisbio (688382.SH) Submits Application to Hong Kong Stock Exchange

Stock News01-02

According to a disclosure by the Hong Kong Stock Exchange on January 1st, Inventisbio Co., Ltd. (Shanghai) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as its sole sponsor. The prospectus reveals that Inventisbio (688382.SH) is an R&D-driven biopharmaceutical company based in China with a global footprint, focusing on major disease areas with significant unmet medical needs, such as oncology, autoimmune diseases, and metabolic diseases. As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products (Befotertinib (BPI-D0316) and Gesso Resai (D 1553)), two core products in the clinical stage (D-2570 and Tairuisiqun (D-0502)), one clinical-stage candidate product (Dabinolei (D-0120)), and three preclinical candidate products (YF087, YF550, and YF057).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143371709?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-02 07:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143371709","market":"us","top_or_hot":-1,"title":"New IPO News | Inventisbio (688382.SH) Submits Application to Hong Kong Stock Exchange","media":"Stock News","content":"<p>According to a disclosure by the Hong Kong Stock Exchange on January 1st, Inventisbio Co., Ltd. (Shanghai) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as its sole sponsor. The prospectus reveals that Inventisbio (688382.SH) is an R&D-driven biopharmaceutical company based in China with a global footprint, focusing on major disease areas with significant unmet medical needs, such as oncology, autoimmune diseases, and metabolic diseases. As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products (Befotertinib (BPI-D0316) and Gesso Resai (D 1553)), two core products in the clinical stage (D-2570 and Tairuisiqun (D-0502)), one clinical-stage candidate product (Dabinolei (D-0120)), and three preclinical candidate products (YF087, YF550, and YF057).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New IPO News | Inventisbio (688382.SH) Submits Application to Hong Kong Stock Exchange</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew IPO News | Inventisbio (688382.SH) Submits Application to Hong Kong Stock Exchange\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-02 07:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to a disclosure by the Hong Kong Stock Exchange on January 1st, Inventisbio Co., Ltd. (Shanghai) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as its sole sponsor. The prospectus reveals that Inventisbio (688382.SH) is an R&D-driven biopharmaceutical company based in China with a global footprint, focusing on major disease areas with significant unmet medical needs, such as oncology, autoimmune diseases, and metabolic diseases. As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products (Befotertinib (BPI-D0316) and Gesso Resai (D 1553)), two core products in the clinical stage (D-2570 and Tairuisiqun (D-0502)), one clinical-stage candidate product (Dabinolei (D-0120)), and three preclinical candidate products (YF087, YF550, and YF057).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FT_SY_HEX","symbol_name":"港交所","start_time":0,"source_url":"","article_id":"1143371709","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143371709","pubTimestamp":1767311776,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to a disclosure by the Hong Kong Stock Exchange on January 1st, Inventisbio Co., Ltd. (Shanghai) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688382":"益方生物","BK0239":"医药制造"},"translate_title":"IPO新动态|英业达生物（688382.SH）向港交所递交申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688382":1,"HEXmain":1},"content_text":"According to a disclosure by the Hong Kong Stock Exchange on January 1st, Inventisbio Co., Ltd. (Shanghai) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as its sole sponsor. The prospectus reveals that Inventisbio (688382.SH) is an R&D-driven biopharmaceutical company based in China with a global footprint, focusing on major disease areas with significant unmet medical needs, such as oncology, autoimmune diseases, and metabolic diseases. As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products (Befotertinib (BPI-D0316) and Gesso Resai (D 1553)), two core products in the clinical stage (D-2570 and Tairuisiqun (D-0502)), one clinical-stage candidate product (Dabinolei (D-0120)), and three preclinical candidate products (YF087, YF550, and YF057).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143371709","isCrawlerRequest":true}